Natalie L Trevaskis

List of Publications by Year
in descending order

68	5,874	172457	102487
papers	citations	29 h-index	66 g-index

68	68	68	5942
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature Reviews Drug Discovery, 2007, 6, 231-248.	46.4	1,446
2	Strategies to Address Low Drug Solubility in Discovery and Development. Pharmacological Reviews, 2013, 65, 315-499.	16.0	1,217
3	From sewer to saviour â€" targeting the lymphatic system to promote drug exposure and activity. Nature Reviews Drug Discovery, 2015, 14, 781-803.	46.4	479
4	Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update. Advanced Drug Delivery Reviews, 2008, 60, 702-716.	13.7	344
5	50 years of oral lipid-based formulations: Provenance, progress and future perspectives. Advanced Drug Delivery Reviews, 2016, 101, 167-194.	13.7	308
6	The mechanisms of pharmacokinetic food-drug interactions â€" A perspective from the UNGAP group. European Journal of Pharmaceutical Sciences, 2019, 134, 31-59.	4.0	224
7	Sex-specific adipose tissue imprinting of regulatory T cells. Nature, 2020, 579, 581-585.	27.8	141
8	From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomaterialia, 2021, 131, 16-40.	8.3	140
9	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences, 2021, 162, 105812.	4.0	137
10	Lipid-Based Formulations and Drug Supersaturation: Harnessing the Unique Benefits of the Lipid Digestion/Absorption Pathway. Pharmaceutical Research, 2013, 30, 2976-2992.	3.5	94
11	Targeted delivery of a model immunomodulator to the lymphatic system: Comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. Journal of Controlled Release, 2014, 177, 1-10.	9.9	76
12	Intestinal Bile Secretion Promotes Drug Absorption from Lipid Colloidal Phases via Induction of Supersaturation. Molecular Pharmaceutics, 2013, 10, 1874-1889.	4.6	67
13	A new in vitro lipid digestion â€" in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations. Pharmaceutical Research, 2016, 33, 970-982.	3.5	58
14	Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity. Nature Metabolism, 2021, 3, 1175-1188.	11.9	56
15	Lymphatic targeting by albumin-hitchhiking: Applications and optimisation. Journal of Controlled Release, 2020, 327, 117-128.	9.9	55
16	Methotrexate-Conjugated PEGylated Dendrimers Show Differential Patterns of Deposition and Activity in Tumor-Burdened Lymph Nodes after Intravenous and Subcutaneous Administration in Rats. Molecular Pharmaceutics, 2015, 12, 432-443.	4.6	51
17	Glycerideâ€Mimetic Prodrugs Incorporating Selfâ€Immolative Spacers Promote Lymphatic Transport, Avoid Firstâ€Pass Metabolism, and Enhance Oral Bioavailability. Angewandte Chemie - International Edition, 2016, 55, 13700-13705.	13.8	50
18	Targeted Drug Delivery to Lymphocytes: A Route to Site-Specific Immunomodulation?. Molecular Pharmaceutics, 2010, 7, 2297-2309.	4.6	48

#	Article	IF	Citations
19	The Lymph Lipid Precursor Pool Is a Key Determinant of Intestinal Lymphatic Drug Transport. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 881-891.	2.5	47
20	Bile Increases Intestinal Lymphatic Drug Transport in the Fasted Rat. Pharmaceutical Research, 2005, 22, 1863-1870.	3.5	43
21	Lipid Absorption Triggers Drug Supersaturation at the Intestinal Unstirred Water Layer and Promotes Drug Absorption from Mixed Micelles. Pharmaceutical Research, 2013, 30, 3045-3058.	3.5	43
22	Intestinal Lymphatic Transport Enhances the Post-Prandial Oral Bioavailability of a Novel Cannabinoid Receptor Agonist Via Avoidance of First-Pass Metabolism. Pharmaceutical Research, 2009, 26, 1486-1495.	3.5	41
23	The Mechanism of Lymphatic Access of Two Cholesteryl Ester Transfer Protein Inhibitors (CP524,515) Tj ETQq1 1 0.784314 rgBT /Ove 2010, 27, 1949-1964.	3.5	36
24	A Mouse Model to Evaluate the Impact of Species, Sex, and Lipid Load on Lymphatic Drug Transport. Pharmaceutical Research, 2013, 30, 3254-3270.	3.5	36
25	The Potential for Drug Supersaturation during Intestinal Processing of Lipid-Based Formulations May Be Enhanced for Basic Drugs. Molecular Pharmaceutics, 2013, 10, 2601-2615.	4.6	36
26	The Role of the Intestinal Lymphatics in the Absorption of Two Highly Lipophilic Cholesterol Ester Transfer Protein Inhibitors (CP524,515 and CP532,623). Pharmaceutical Research, 2010, 27, 878-893.	3.5	35
27	Lymphatic Transport and Lymphocyte Targeting of a Triglyceride Mimetic Prodrug Is Enhanced in a Large Animal Model: Studies in Greyhound Dogs. Molecular Pharmaceutics, 2016, 13, 3351-3361.	4.6	34
28	AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT. Drug Metabolism and Disposition, 2006, 34, 729-733.	3.3	33
29	Profiling the Role of Deacylation-Reacylation in the Lymphatic Transport of a Triglyceride-Mimetic Prodrug. Pharmaceutical Research, 2015, 32, 1830-1844.	3.5	29
30	Lymphatic Uptake of Liposomes after Intraperitoneal Administration Primarily Occurs via the Diaphragmatic Lymphatics and is Dependent on Liposome Surface Properties. Molecular Pharmaceutics, 2019, 16, 4987-4999.	4.6	28
31	The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport. Journal of Visualized Experiments, 2015, , .	0.3	27
32	The Impact of Lymphatic Transport on the Systemic Disposition of Lipophilic Drugs. Journal of Pharmaceutical Sciences, 2013, 102, 2395-2408.	3.3	25
33	Intestinal Lymph Flow, and Lipid and Drug Transport Scale Allometrically From Pre-clinical Species to Humans. Frontiers in Physiology, 2020, 11, 458.	2.8	23
34	Targeting immune cells within lymph nodes. Nature Nanotechnology, 2020, 15, 423-425.	31.5	21
35	Single Intravenous Dose of Novel Flurbiprofen-Loaded Proniosome Formulations Provides Prolonged Systemic Exposure and Anti-inflammatory Effect. Molecular Pharmaceutics, 2016, 13, 3688-3699.	4.6	20
36	Lymph-directed immunotherapy â€“ Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer. Advanced Drug Delivery Reviews, 2020, 160, 115-135.	13.7	18

#	Article	IF	Citations
37	Fatty Acid Binding Proteins: Potential Chaperones of Cytosolic Drug Transport in the Enterocyte?. Pharmaceutical Research, 2011, 28, 2176-2190.	3.5	17
38	Constitutive Triglyceride Turnover into the Mesenteric Lymph Is Unable to Support Efficient Lymphatic Transport of a Biomimetic Triglyceride Prodrug. Journal of Pharmaceutical Sciences, 2016, 105, 786-796.	3.3	17
39	Recent Advances in Lipid-Based Formulation Technology. Pharmaceutical Research, 2013, 30, 2971-2975.	3.5	16
40	Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods. Molecular Pharmaceutics, 2017, 14, 394-405.	4.6	16
41	Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery. Journal of Controlled Release, 2018, 272, 17-28.	9.9	16
42	Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in mice. Journal of Controlled Release, 2021, 332, 636-651.	9.9	16
43	Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. Journal of Controlled Release, 2022, 341, 676-701.	9.9	16
44	In vitroâ€“in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 973-985.	4.3	15
45	Organ-specific lymphatics play distinct roles in regulating HDL trafficking and composition. American Journal of Physiology - Renal Physiology, 2020, 318, G725-G735.	3.4	15
46	Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623. Molecular Pharmaceutics, 2017, 14, 4525-4538.	4.6	14
47	Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles. Pharmaceutical Research, 2021, 38, 1497-1518.	3.5	14
48	Therapeutic delivery to the peritoneal lymphatics: Current understanding, potential treatment benefits and future prospects. International Journal of Pharmaceutics, 2019, 567, 118456.	5.2	13
49	Intravenous Dosing Conditions May Affect Systemic Clearance for Highly Lipophilic Drugs: Implications for Lymphatic Transport and Absolute Bioavailability Studies. Journal of Pharmaceutical Sciences, 2012, 101, 3540-3546.	3.3	12
50	Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation. Journal of Controlled Release, 2019, 296, 29-39.	9.9	12
51	High-Density Lipoprotein Composition Influences Lymphatic Transport after Subcutaneous Administration. Molecular Pharmaceutics, 2020, 17, 2938-2951.	4.6	12
52	Lymphatic contractile function: a comprehensive review of drug effects and potential clinical application. Cardiovascular Research, 2022, 118, 2437-2457.	3.8	11
53	Tissue uptake of DDT is independent of chylomicron metabolism. Archives of Toxicology, 2006, 80, 196-200.	4.2	10
54	Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistat. International Journal of Pharmaceutics, 2021, 596, 120247.	5.2	10

#	Article	IF	Citations
55	An Acute and Coincident Increase in FABP Expression and Lymphatic Lipid and Drug Transport Occurs During Intestinal Infusion of Lipid-Based Drug Formulations to Rats. Pharmaceutical Research, 2006, 23, 1786-1796.	3.5	8
56	The Impact of Conjugation Position and Linker Chemistry on the Lymphatic Transport of a Series of Glyceride and Phospholipid Mimetic Prodrugs. Journal of Pharmaceutical Sciences, 2021, 110, 489-499.	3.3	8
57	Intra-articular injection of biologic anti-rheumatic drugs enhances local exposure to the joint-draining lymphatics. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 173, 34-44.	4.3	8
58	The Gut-Lymph Model Gives New Treatment Strategies for Organ Failure. JAMA Surgery, 2022, 157, 540.	4.3	7
59	Acute Hypertriglyceridemia Promotes Intestinal Lymphatic Lipid and Drug Transport: A Positive Feedback Mechanism in Lipid and Drug Absorption. Molecular Pharmaceutics, 2011, 8, 1132-1139.	4.6	5
60	Correction to â€œTargeted Drug Delivery to Lymphocytes: A Route to Site-Specific Immunomodulation?â€• Molecular Pharmaceutics, 2011, 8, 2484-2484.	4.6	4
61	Glycerideâ€Mimetic Prodrugs Incorporating Selfâ€Immolative Spacers Promote Lymphatic Transport, Avoid Firstâ€Pass Metabolism, and Enhance Oral Bioavailability. Angewandte Chemie, 2016, 128, 13904-13909.	2.0	4
62	Vmeasur: A software package for experimental and clinical measurement of mesenteric lymphatic contractile function over an extended vessel length. Microcirculation, 2022, , e12748.	1.8	4
63	Methods for studying pulmonary lymphatics. European Respiratory Journal, 2021, 57, 2004106.	6.7	3
64	Intestinal lymphatic dysfunction: a new pathway mediating gutâ€“kidney crosstalk in kidney disease. Kidney International, 2021, 100, 511-513.	5.2	2
65	Association of a vaccine adjuvant with endogenous HDL increases lymph uptake and dendritic cell activation. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 172, 240-252.	4.3	2
66	Frontispiece: Glycerideâ€Mimetic Prodrugs Incorporating Selfâ€Immolative Spacers Promote Lymphatic Transport, Avoid Firstâ€Pass Metabolism, and Enhance Oral Bioavailability. Angewandte Chemie - International Edition, 2016, 55, .	13.8	1
67	Frontispiz: Glycerideâ€Mimetic Prodrugs Incorporating Selfâ€Immolative Spacers Promote Lymphatic Transport, Avoid Firstâ€Pass Metabolism, and Enhance Oral Bioavailability. Angewandte Chemie, 2016, 128, .	2.0	0
68	Editorial: Modulating Vascular Lymphatic Growth in Disease: Current and Potential Pharmacological Approaches for Prevention and Treatment. Frontiers in Pharmacology, 2022, 13, 910142.	3.5	0